HIV-1 Integrase Inhibitor Resistance by Sequencing
2004457
Ordering Recommendation
Submit With Order
Mnemonic
HIV1INT
Methodology
Reverse Transcription Polymerase Chain Reaction/Sequencing
Performed
Tue, Fri
Reported
7-10 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA), pink (K2EDTA), or plasma preparation tube.  
Specimen Preparation
Separate plasma from cells within 6 hours. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)  
Storage/Transport Temperature
Frozen.  
Unacceptable Conditions
Serum. Heparinized specimens.  
Remarks
Please submit most recent viral load and test date, if available.  
Stability
On cells: Ambient: 6 hours; After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 4 months  
Reference Interval
By report
Interpretive Data
The entire integrase-encoding region is sequenced. Mutations associated with resistance to integrase inhibitors are reported. Mutations in viral sub-populations below 20 percent of total may not be detected.

See Compliance Statement D: www.aruplab.com/CS
Note
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 HIV-1 RNA copies per mL of plasma.
CPT Code(s)
87906
Components
Component Test Code*Component Chart Name
2004458HIV-1 Integrase Inhib. Resistance, Seq
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • HIV Drug Resistance
  • HIV Integrase Genotype
  • HIV Integrase Inhibitor Resistance
  • HIV Treatment Susceptibility Testing
  • HIV1 Integrase Resistance
  • HIV1 Integrase Sequencing
  • HIV1 Sequencing
  • Raltegravir (Isentress(TM)) Resistance